|Bid||21.30 x 800|
|Ask||21.32 x 900|
|Day's Range||20.85 - 21.84|
|52 Week Range||5.12 - 25.10|
|Beta (3Y Monthly)||4.38|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HENDERSON, NV / ACCESSWIRE / February 15, 2019 / With Cannabis companies already having an amazing 2019, we decided to hunt for the next potential breakout candidate. We searched amongst lesser known companies ...
Marijuana stocks and related ETFs caught investors' attention last year, courtesy of its mysterious rally in mid-2018 on Canada's legalization of recreational marijuana in October. Let's take a look at whether the space will be able to maintain its rally in 2019.
Canopy Growth Rises after Earnings BeatCanopy Growth risesCanopy Growth (WEED) (CGC) was trending higher by 5% when markets opened. The company reported its earnings late last evening at around 8:45 PM EST.The company reported strong top-line
HENDERSON, NV / ACCESSWIRE / February 15, 2019 / Cannabis stocks are having an incredible 2019 thus far. The sector appeared to have peaked in the fall of 2018. When Canada's legalization went into effect, ...
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aphria Inc (APHA), Canopy Growth Corp (CGC), and Cronos Group Inc (CRON) represent four pot stocks looking to close out a strong week. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is unlike many companies in the cannabis sector because its core framework is built around healthcare. The Company is largely focused on meeting the growing challenges of the healthcare industry through investments in advanced telemedical technologies and other innovations.
The medical marijuana firm jumped 3% midday, despite its revenue of $62.35 million missing Investing.com estimates of $66 million.
After being beaten down in the final quarter of 2018, pot stocks staged a nice comeback at the start of this year on the renewed appeal for riskier assets. Here's why ETFs are riding high this year.
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aurora Cannabis Inc (NYSE: ACB, TSX: ACB), Cronos Group Inc (CRON), and New Age Beverages Corporation (NBEV) represent four cannabis worth keeping on your radar. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to meet the challenges of our ever-evolving healthcare system. The Company's subsidiary, HealthVue, currently boasts an ecosystem of over 100,000 active patients and plans to rapidly increase that number both domestically and internationally.
HENDERSON, NV / ACCESSWIRE / February 14, 2019 / Below are several cannabis companies you do not want to miss the boat on. One in particular is already starting to make its investors serious gains: CleanSpark, ...
Whether its eating a gooey, chocolatey brownie or taking a few hits off a freshly rolled joint, it???s common knowledge that a lot of people like to get high. Many investors, however, have yet to "light up." What are the best marijuana stocks out there right now?
With Aurora Cannabis and most other marijuana stocks, sentiment and short squeezes are directing price action.
The 2019 Benzinga Cannabis Capital Conference in Miami Beach included investor presentations from KushCo, Medicine Man and other major companies in the space. California-based Kushco, which began as a packaging company, is primarily focused on being as much of a business-to-business company as possible, Christoffersen said.
For the fourth consecutive quarter, Philip Morris (NYSE:PM) beat earnings estimates. The New York-based international tobacco company reported higher-than-expected numbers on both the top and bottom lines. Although both profits and revenue fell on a year-over-year basis, investors reacted well to the news, bidding PM stock higher each of the following two days. * 7 Forever Stocks to Buy for Long-Term Gains However, with its high dividend, most investors focus on the payout. The generous yield, along with the 11-year streak of increases, has drawn investors into Philip Morris stock since the beginning. However, investors may want to approach PM stock dividend cautiously, as it faces an unexpected danger. Earnings, Revenue Beat Boosted PM StockFor the fourth quarter, the company reported non-GAAP earnings of $1.25 per share. This came in eight cents ahead of analyst expectations. Despite the higher-than-expected earnings, it still represents a year-over-year drop as PM earned $1.32 per share in the same quarter last year. Revenues of $7.5 billion also beat estimates by $110 million. Still, they fell by 9.5% from last year's $8.29 billion in the year-ago quarter.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvestors took the news well as PM stock rose by about 1.6% in Thursday trading. It increased by an additional 4.2% on Friday.Much like its former parent Altria (NYSE:MO), PM stock has dealt with the poor reputation and the marginalization of its core product. However, PM tends to maintain its profit growth. The company has also introduced IQOS, a "heat, not burn" smokeless product. It plans to ultimately replace cigarettes with IQOS in the coming years and that may boost profits as well.PM has also maintained steady growth is in its dividend. The company has increased the payout every year since its split off from Altria in 2008. The annual payout for this year will amount to $4.56 per share. This gives today's buyer a yield of about 5.7%.The PM stock price has grown by only 150% of its value since the March 2009 low. Since this significantly lags the 345% increase seen in the S&P 500 over the same period, most stockholders own PM for its dividend. Here investors need to exercise caution. Beware the Payout RatioActivists have long targeted tobacco and have increasingly disliked PM's smokeless alternative. However, the most immediate danger to PM does not lie there. The near-term threat with PM stock lies in its dividend payout ratio -- the percentage of net income paid out in dividends.The dividend payout ratio has risen to over 85%. Consumer defensive issues like Philip Morris stock tend to maintain higher payout ratios. However, even in PM's sector, they typically remain well under 85%. The company's reduced profit should cause concern. If that pace were to continue, PM could place itself in a position where it pays out more in dividends than it earns.Fortunately, analysts believe it can avert this fate. Wall Street forecasts an average growth rate of about 6% per year over the next five years. Alternative lines of business also remain an option. IQOS receives most of the attention in that area. Also, much like Altria invested in Cronos (NASDAQ:CRON), it could enter the cannabis sector. Philip Morris has so far given no indication it has such plans.Still, unless PM sees higher levels of profit growth, dividend growth should remain a major concern. If Philip Morris reports lower revenues and profits, I would recommend getting out before the inevitable dividend cut. The Bottom Line on PM StockThe dividend payout ratio on PM stock poses a more immediate threat to the equity than the reputation of its core product. Philip Morris continues to earn profits. However, the company reported lower profits than last year. This creates a precarious situation, as the company tends to increase its dividend annually and pay out nearly all of its profits in the form of dividends. Any interruption to these increases will devastate PM stock. * 12 2018 Winners That Will Be Big Ol' Losers in 2019 For now, analysts expect profit growth to resume. It has invested heavily in its smokeless product and, like its U.S.-focused counterpart, it could also enter the cannabis market. However, profit growth has become paramount. If profits continue to fall, investors need to smoke PM stock out.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks That Every 20-Year-Old Should Buy * 10 Best Dividend Stocks to Buy for the Next 10 Months * 10 Monster Growth Stocks to Buy for 2019 and Beyond Compare Brokers The post An Unexpected Danger Could Smoke Philip Morris Stock appeared first on InvestorPlace.
Why Altria Is Betting Big on JUUL Labs and Cronos Group(Continued from Prior Part)Altria’s investment On December 20, Altria Group (MO) announced a $12.8 billion investment in JUUL Labs for a 35% stake in the e-cigarette company. According to the
Aurora Cannabis (NYSE:ACB) has been a rocket this year, with Aurora Cannabis stock spiking about 44%. But things got off to a rocky start this week when the shares dropped by 5%. The main concern for ACB stock investors? The upcoming earnings report. Although the stock has since recovered some of the losses, it's still worth a deeper look into their concerns. Click to Enlarge Source: Shutterstock So let's take a look at the fiscal second-quarter results.Revenue came close to quadrupling to C$54.2 million (in Canadian dollars), while the Street was looking for C$51.84 million (although, there are only two analysts with estimates). Last month, ACB issued its own forecast, which called for the top-line to range from C$50 million and C$55 million.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis hyper-growth should be no surprise. In October, the Canadian government legalized cannabis for recreational purposes. While there were supply issues and other snafus, the demand was off-the-charts. Note that ACB generated C$21.6 million from the consumer category in the quarter. This came to roughly 20% of marketshare.However, ACB's bottom line was far from inspiring. The company posted a massive loss of C$237.8 million, which was mostly due to charges from investments in cannabis companies. Keep in mind that the company is required to make adjustments to changes in market values.There was also deterioration in gross margins, which is probably the biggest factor impacting Aurora Cannabis stock. They plunged from 70% to 54% on a quarter-over-quarter basis. * 10 Stocks That Every 20-Year-Old Should Buy But on the earnings call, CFO Glen Ibbott noted that the company should be able to reach EBITDA positive by fiscal Q4. He also showed that the company has been disciplined with operating costs. And yes, there should be a big help from surging revenues and improvements in the production process.In the meantime, the medical business continues to get traction. There are currently over 73,000 patients in Canada and ACB is conducting 40 clinical trials and seven pre-clinical studies. Even just a few drug launches could have a major impact on revenues.All this means that high-quality production at scale is critical. To this end, ACB is running at annual production of about 120,000 kilograms and this is expected to increase by 30,000 within a month or so. Bottom Line on Aurora Cannabis StockACB stock is far from cheap. Consider that the market cap is at a hefty $7.3 billion. But then again, the rest of the sector is trading at premium valuations, as seen with Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY) and Cronos Group (NASDAQ:CRON).But this is to be expected because of the massive growth opportunities in the sector. According to Altria (NYSE:MO) CEO Howard Willard, the spending on cannabis is expected to reach $40 billion within the next ten years on a global basis. As a testament to his enthusiasm for the sector, he recently invested $1.8 billion in CRON.As for ACB, it has leveraged its highly valued stock to pull off aggressive M&A. This has allowed the company to gain important footholds in areas like Europe and South America (there is now a presence in 22 countries across five continents). ACB also has been able to assemble a large retail business in Canada.Now as for Aurora Cannabis stock, there will be continued volatility. This is normal for any high-growth company. Besides, the business is diversified, well funded (with a recent convertible note offering of $345 million) and the M&A strategy looks spot on. In other words, for those looking for a play on cannabis, ACB stock is a pretty good choice.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks That Every 20-Year-Old Should Buy * 10 Best Dividend Stocks to Buy for the Next 10 Months * 10 Monster Growth Stocks to Buy for 2019 and Beyond Compare Brokers The post Is Aurora Cannabis Stock Worth a Buy on Stratospheric Sales? appeared first on InvestorPlace.
Aurora Cannabis Provides Updates on Hemp and Softgel Format in Q2Hemp update Aurora Cannabis (ACB) reported its earnings yesterday and provided some key insights into its hemp business activity. On its earnings call, Aurora Cannabis stated that its
Aurora Cannabis: Key Takeaways from Its Q2 EarningsSecond-quarter earningsOn February 11, Aurora Cannabis (ACB) reported its second-quarter earnings after the market closed. The company beat the top-line (revenue) estimates but missed the
HENDERSON, NV / ACCESSWIRE / February 12, 2019 / Below are several companies in the biotech space that are making news and drawing investor interest. These companies have the potential to make investors ...
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
As marijuana stocks have rallied recently, many investors have gotten in over their heads. For both groups, investors are forgetting that marijuana stocks can be volatile. When I wrote “How to potentially become a marijuana millionaire, albeit carefully,” the most important word in the headline was “carefully.” Some will gain, but many more will lose.
This past week's downgrade of Cronos Group (NASDAQ:CRON) rekindled an overdue discussion about the real value of CRON stock and pot stocks more broadly. Click to Enlarge Source: Shutterstock GMP Securities analyst Martin Landry lowered the firm's stance on Cronos Group stock from "Buy," to "Hold," not because he feels the company has hit a wall, but because CRON stock appears to have rallied too far, too fast. While not his direct intention, Landry's comments also assured less-daring investors missing out on cannabis-mania that their doubts weren't entirely unmerited. * 10 Best Dividend Stocks to Buy for the Next 10 Months More important, the marijuana craze has still lured a huge number of unsuspecting traders into a trap. The only thing really keeping these names propped up right now is hype, but hype can fade fast, and without warning.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cronos Stock and the Big RunLandry's exact words:"The company's shares have surged ~110% year-to-date on no material news and have outperformed the HMMJ cannabis index by a factor of 2. This strong performance forces us to change our rating to HOLD solely based on valuation."The GMP Securities analyst further fleshed out that Cronos is still well-positioned to capture a respectable piece of a very real but budding marijuana market. The time Cronos needs to fully figure out where it fits in an ever-changing market, however, could prove turbulent for Cronos stock.Landry went on to caution investors:"Cronos is still in the early stage of its development with limited revenues in relation to its sizable market cap. Hence, in our view, the company needs to backfill its valuation with capital deployment into the U.S. market, increase its penetration in the Canadian recreational market and continue its international expansion."It was a well-reasoned, common-sense observation and too many traders would have none of it.That dynamic has been in place for months, largely starting on the heels of news that Constellation Brands (NYSE:STZ) had made a major investment in Canopy Growth (NYSE:CGC).Shortly thereafter, Altria Group (NYSE:MO) bought $2 billion worth of Cronos stock, solidifying the idea that not only did cannabis have a bright future, but a wave of deal-making and outright acquisitions was imminent.That wave isn't quite as imminent as some have been hoping. Despite the overly-aggressive pushback against his point, that's all Landry was really trying to say. The Hype Feels RealFor the relatively small but highly vocal horde of investors who not only bought heavily into Cronos, but bought into the very premise of the cannabis movement itself, it is tough news to hear.They're not wrong to be optimistic; the marijuana legalization movement is steam-rolling its way across the world.Their expectations and timeframes, however, are uncomfortably aggressive.We've seen it happen before. Think back to 2013. That was the rise of the affordable (sort of) 3D printers, which were supposed to revolutionize small-scale manufacturing. And they did, to some degree. Investors who bought into the idea of the craze at the time were severely punished though.3D Systems (NYSE:DDD), a poster child of the 3D printing revolution unfurling at the time, soared from $12 per share near the beginning of 2012 to a peak of more than $80 in 2013. By late-2015, it was back under $9 per share, with 3D printers never living up to their full hype.Another proverbial failure-to-launch: The 2012 race between Arena Pharmaceuticals (NASDAQ:ARNA) and Orexigen Therapeutics (OTCMKTS:OREXQ) to introduce the first FDA-approved weight-loss drug to the U.S. market in thirteen years.Both stocks soared on their respective prospects, but neither stock has ever been priced as high as they were right around the times of their approvals. Neither drug has met lofty sales expectations being batted around them. Orexigen, in fact, has since declared bankruptcy.Investors were certain at the time, of course, that could never happen. The buzz was too strong.Add solar panels, cryptocurrency, real estate in 2008, dot-coms in 2000, wearables, and a hundred others to the lists of investing letdowns. They all still have a place, and offer select investment opportunities to be sure.They've all, however, pulled the rug out from underneath early-cycle investors that loved the premise but ignored the plausible math.Yet, somehow the "this time is different" argument is being recycled, indicating investors believe pot stocks will never see any serious downside again. Bottom Line for Cronos StockOr, perhaps this time truly is different. Never say never. If we're thinking realistically though, it's naive to not suspect the ongoing legitimization of marijuana won't draw bigger players into the arena before outfits like Cronos get a chance to fully take rook and make a buck.Such a development sets the stage for potential acquisitions. Indeed, bigger players have already tiptoed into partial ownership. That bodes well for Cronos Group stock.Those would-be buyers have far more time to let the dust settle than most M&A-minded investors care to believe though. That leaves plenty of time to wear the polish off of CRON stock and its peers, and let the reality of debt and heavy spending tarnish the shine.Still, there's no denying Cronos Group stock will make for some great swing trading, the next one of which should be pointed down. GMP Securities' Landry couldn't be quite that blunt, of course.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Fundamentally Sound Dividend Stocks to Buy * 5 Reasons Reeling FAANG Stocks Won't Deliver Big Returns * 3 Reasons Canopy Growth Could Burn You Compare Brokers The post Don't Get Trapped by All the Hype Surrounding Cronos Stock appeared first on InvestorPlace.
Yahoo Finance's Alexis Keenan interviews Michael Dundas, CEO of Sira Naturals, on The Final Round from The Seed to Sale Show in Boston to talk about the latest trends in the cannabis industry.